NeoPharm files IND for LE-AON

NEOL filed an IND with the FDA for clinical testing of Liposomal Encapsulated Antisense Oligonucleotide ( LE-AON) which targets the c- raf-1 oncogene to treat patients with radiation resistant tumors....